Answers are grounded in this paper and cite their sources.
Background Diabetes mellitus and depression frequently coexist and may share inflammatory, metabolic, neuroendocrine, and behavioral pathways. The intestinal microbiome may represent a biological interface linking metabolic dysfunction with depressive symptoms, but direct human evidence in populations with diabetes remains limited. Objective To systematically synthesize direct human evidence on intestinal microbiome alterations associated with depression or depressive symptoms among people with diabetes and interpret the findings within a gut-metabolic-brain axis framework. Methods This systematic review followed PRISMA 2020, with search reporting informed by PRISMA-S. Eight databases were searched through August 27, 2026, supplemented by ClinicalTrials.gov, Google Scholar, Research4Life/HINARI, reference lists, and citation tracking. Eligible studies assessed diabetes, depression or depressive symptoms, and intestinal/fecal microbiome data within the same participant sample. Contextual studies not meeting these criteria were considered separately. Owing to substantial clinical and methodological heterogeneity, findings were synthesized qualitatively rather than by meta-analysis. Results Database searches identified 1,293 records, with 61 additional unique records from ClinicalTrials.gov. After removing 497 duplicates, 857 records were screened, 94 full-text reports were assessed, and five eligible reports met the eligibility criteria. Three involved type 1 diabetes populations, while two were randomized dietary intervention studies in type 2 diabetes. Across studies, depression or depressive symptoms were associated with differences in intestinal microbial composition and microbiome-related metabolic or neurobiological measures; however, findings varied considerably according to study design, population, depression assessment, and microbiome methodology. Conclusion Direct human evidence suggests that depression or depressive symptoms in people with diabetes may be associated with alterations in the intestinal microbiome and related metabolic and neurobiological measures. However, the direct evidence base remains small and heterogeneous, and the available findings are better regarded as hypothesis-generating biological signals than evidence of a consistent microbial signature or causal microbiome-mediated pathway. Larger longitudinal, multi-omics, and intervention studies using standardized microbiome methods, validated depression measures, rigorous confounder adjustment, and mediation analyses are needed.
No takes yet. Share an insight, caveat, or question.
Albasheer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: